Navigation Links
KemPharm, Inc. to Present at the Canaccord Genuity 34th Annual Growth Conference

CORALVILLE, Iowa, Aug. 6, 2014 /PRNewswire/ -- KemPharm, Inc., a clinical stage biopharmaceutical company focused on the discovery and development of new, safer therapies to treat pain, announced today that President and CEO, Travis Mickle, Ph.D., will present at the Canaccord Genuity 34th Annual Growth Conference at the InterContinental Boston Hotel in Boston, MA.

Among the topics to be discussed, Dr. Mickle will provide an overview of KemPharm's clinical, regulatory and commercial strategy for KP201, the company's lead clinical candidate for the treatment of acute moderate to moderately severe pain.  Composed of hydrocodone chemically bound to a ligand, KP201 offers unique physicochemical and pharmacological attributes that may deliver additional patient benefits, including reduced potential for abuse and reduction or elimination of opioid-induced constipation (OIC). 

Details of KemPharm's presentation are as follows: Event:Canaccord Genuity 34th Annual Growth ConferenceDate: August 13, 2014Time: 11:00 a.m. – 11:25 a.m. ETLocation:InterContinental Boston HotelAbout KemPharmKemPharm is a biopharmaceutical company focused on the discovery and development of new chemical entities (NCEs) to treat serious medical conditions through its proprietary and broadly applicable Ligand Activated Therapy (LAT) approach.  The company utilizes its LAT technology to generate improved prodrug versions of FDA approved drugs in the high needs areas of pain, ADHD and other CNS diseases.  For more information on KemPharm, please visit the company's website at KemPharm, Inc:Media / Investor Contacts:Gordon K. "Rusty" Johnson


Jason Rando / Joshua Drumm, Ph.D.

Tiberend Strategic Advisors, Inc.

212.375.2665 / 2664

SOURCE KemPharm, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. KemPharm, Inc. Receives Patent from the USPTO for Novel Pain Drug Candidate, KP201
2. MEI Pharma To Present At Wedbush PacGrow Life Sciences And Canaccord Genuity Growth Conferences
3. Cynosure to Present at Canaccord Genuity 34th Annual Growth Conference
4. IRIDEX to Present at 2014 Wedbush Life Sciences Management Access Conference
5. HeartWare Presentation At The Canaccord Genuity 34th Annual Growth Conference To Be Webcast
6. CryoLife to Present at 34th Annual Canaccord Genuity Growth Conference
7. Volcano Corporation Presentation At Canaccord Genuity Conference To Be Webcast
8. Xencor to Present at Wedbush Securities 2014 Life Sciences Management Access Conference
9. Cardica To Present At 2014 Wedbush PacGrow Life Sciences Management Access Conference
10. Thoratec Presentation At Canaccord Genuity Growth Conference To Be Webcast
11. Rock Creek Pharmaceuticals to Present at the Annual BioPharm America International Partnering Conference
Post Your Comments:
(Date:11/25/2015)... -- Today AVACEN Medical announced the issue of United States patent No. 9,192,509 ... This patent shields the company,s AVACEN 100 dry heat therapy medical device and specific methods of ... Photo - ... ... ...
(Date:11/25/2015)... -- Endo International plc (NASDAQ: ENDP ) (TSX: ENL) ... CEO, will discuss corporate updates at the 27 th ... on Wednesday, December 2, 2015 at 1 p.m. ... and then the link to the event. Participants should allow ... visit the site and download any streaming media software needed ...
(Date:11/25/2015)... November 25, 2015 --> ... blood glucose devices was valued at $11,171.1 million in ... CAGR of 5.7% during 2015 - 2022. The global ... increasing prevalence of diabetes. In addition, the increase in ... also contributing to the growth of the market. Furthermore, ...
Breaking Medicine Technology:
(Date:11/24/2015)... ... ... Charitable giving is at its peak during the holidays. In fact, ... the year totalling over $358 billion in 2014. With more than 1.5 million ... individuals who want to “give back” during the holidays. , “With so many charities ...
(Date:11/24/2015)... ... November 24, 2015 , ... In an article ... variables that determine which patients are or are not eligible for bariatric surgery. The ... BMI over 40, are more than 100 pounds overweight, or have a BMI of ...
(Date:11/24/2015)... ... ... DMG Productions announced that they will feature Aphria, Inc., in an upcoming episode ... and show times TBA. , Aphria, Inc., is a publicly traded company incorporated under ... medical marijuana pursuant to the Marijuana for Medical Purposes Regulations (the “MMPR”). , Aphria ...
(Date:11/24/2015)... ... ... Preparing for the LDT Regulation:, CLIA Won’t Satisfy the FDA, Dec. ... has long asserted that design and manufacture of Laboratory Developed Tests (LDTs) falls under ... the device regulations. , Come up short in an inspection and the FDA can ...
(Date:11/24/2015)... ... November 24, 2015 , ... ... organization will waive paid entry and parking fees at several of their most ... Mountain in Great Barrington in support of REI’s Black Friday #OptOutside Campaign. The ...
Breaking Medicine News(10 mins):